Neuromuscular Disease

Muscular dystrophies are a group of diseases that cause weakness and degeneration of the skeletal muscles. At the CHEO Research Institute, much of our research is focused on Duchenne Muscular Dystrophy (DMD), one of nine types of muscular dystrophy. DMD is a genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. The disease primarily affects boys and in rare cases can affect girls. The past decade has seen tremendous advances in the diagnosis and treatment of DMD. These advances have led to an improved outlook for those living with the condition, translating into heightened optimism within the DMD community.

Related News

Research Projects

  1. Utility and practice of electrodiagnostic testing in the pediatric population: An AANEM consensus statement

    02/11/2019

    The panel found that electrodiagnostic studies continue to have high utility for the diagnosis of numerous childhood neuromuscular disorders, and that standardized approaches along with the use of high‐quality reference values are important to maximize the diagnostic yield of these tests in infants, children, and adolescents.

  2. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome

    04/07/2019

    Motor neurons contact their target muscle fibres at highly specialised chemical synapses, neuromuscular junctions (NMJ).

  3. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

    15/06/2019

    Significantly greater clinical improvements were shown in rickets severity, growth, and biochemistries among children with X-linked hypophosphataemia treated with burosumab compared with those continuing conventional therapy.

  4. Long-Term Effects of Lung Volume Recruitment on Maximal Inspiratory Capacity and Vital Capacity in Duchenne Muscular Dystrophy

    08/07/2015

    With lung volume recruitment therapy, MIC–VC differences were stable over time, indicating that respiratory system compliance remains stable, despite a loss in VC, in individuals with Duchenne muscular dystrophy.

  5. Targeted therapies for congenital myasthenic syndromes: systematic review and steps towards a treatabolome

    We assess the strength and quality of the evidence and create a dataset that provides the foundation for a computer-aided system to enable clinicians to gain easier access to information about treatable variants and the evidence they need to consider.

Researchers

  1. Kyle Cowan

    Scientist, CHEO Research Institute

    View Profile Email
  2. Sherri Katz

    Senior Scientist, CHEO Research Institute

    View Profile Email
  3. Robert Korneluk

    Senior Scientist, CHEO Research Institute

    View Profile Email
  4. Hanns Lochmüller

    Senior Scientist, CHEO Research Institute

    View Profile Email
  5. Alex MacKenzie

    Senior Scientist, CHEO Research Institute

    View Profile Email
  6. Hugh McMillan

    Investigator, CHEO Research Institute

    View Profile Email
  7. Leanne Ward

    Senior Scientist, CHEO Research Institute

    View Profile Email
  8. Jodi Warman

    Scientist, CHEO Research Institute

    View Profile Email

Family Leaders

  1. Keira Danson

    View Profile
  2. Sheena Murphy

    View Profile